Constipation-predominant irritable bowel syndrome: a review of current and emerging drug therapies.
about
Saccharomyces cerevisiae CNCM I-3856 in irritable bowel syndrome: An individual subject meta-analysis.Stress-induced visceral pain: toward animal models of irritable-bowel syndrome and associated comorbidities.Optimal management of constipation associated with irritable bowel syndromeEffect of the probiotic strain Bifidobacterium animalis subsp. lactis, BB-12®, on defecation frequency in healthy subjects with low defecation frequency and abdominal discomfort: a randomised, double-blind, placebo-controlled, parallel-group trial.Effects of baseline abdominal pain and bloating on response to lubiprostone in patients with irritable bowel syndrome with constipation.Formulary Drug Reviews: Plecanatide.
P2860
Constipation-predominant irritable bowel syndrome: a review of current and emerging drug therapies.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Constipation-predominant irrit ...... t and emerging drug therapies.
@ast
Constipation-predominant irrit ...... t and emerging drug therapies.
@en
type
label
Constipation-predominant irrit ...... t and emerging drug therapies.
@ast
Constipation-predominant irrit ...... t and emerging drug therapies.
@en
prefLabel
Constipation-predominant irrit ...... t and emerging drug therapies.
@ast
Constipation-predominant irrit ...... t and emerging drug therapies.
@en
P2860
P356
P1476
Constipation-predominant irrit ...... t and emerging drug therapies.
@en
P2093
Khaled A Jadallah
Susan M Kullab
P2860
P304
P356
10.3748/WJG.V20.I27.8898
P407
P577
2014-07-01T00:00:00Z